"Never attribute to malice that which can be adequately explained by stupidity." - Robert J. Hanlon
It has been two months since we positively profiled Theravance Biopharma (TBPH). The stock is up some 35% since then and has been particularly strong over the past couple of weeks. With a key potential catalyst on the horizon before year end 2018, we thought we would revisit this rallying small cap biotech name.
Company Overview
Theravance was founded in 2013 to create novel and potentially best-in-class therapeutics to address the unmet needs of patients being